Hexarelin / CJC-1295 provides an analytical reference standard combining a high-potency Growth Hormone Secretagogue Receptor agonist (Hexarelin) with a GHRH analogue (CJC-1295 No DAC). Engineered to investigate synergistic somatotropic signaling, CJC-1295 mediates cAMP/PKA gene transcription while Hexarelin mediates vesicular exocytosis and CD36 scavenger receptor cascades.
$79.00
In stock
| Quantity | Discounted Price |
|---|---|
| 4 - 6 | $75.84 |
| 7 - 9 | $74.26 |
| 10 + | $72.68 |
The Hexarelin / CJC-1295 Complex is an advanced dual-peptide analytical reference standard combining two complementary, non-competitive secretagogues within a precise 7.5mg / 5mg stoichiometric ratio (12.5mg total peptide mass per vial). This formulation pairs Hexarelin (Examorelin) (a synthetic hexapeptide ghrelin receptor agonist) with CJC-1295 (also known as Modified GRF 1-29 / CJC-1295 No DAC, a tetrasubstituted GHRH analogue).
In adenohypophyseal somatotrope modeling, single-pathway receptor stimulation is restricted by homeostatic rate limitations. CJC-1295 (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2) selectively binds Gαs-protein coupled GHRH receptors on anterior pituitary somatotropes. Receptor occupancy activates adenylate cyclase, elevating intracellular cyclic AMP (cAMP) and activating Protein Kinase A (PKA) to drive growth hormone (GH) gene transcription and synthesis.
Concurrently, Hexarelin (His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2) engages the Gq/11-coupled Growth Hormone Secretagogue Receptor (GHSR-1a), activating Phospholipase C (PLC) and inositol trisphosphate (IP3) to mobilize intracellular calcium (Ca2+) and drive the rapid exocytosis of pre-formed hormone granules. Additionally, Hexarelin selectively binds the scavenger receptor CD36, enabling researchers to explore localized metabolic and cytoprotective cascades independently of pituitary hormone release.
Batch-verified for high analytical purity and exact stoichiometric recovery at Modern Aminos, the Hexarelin / CJC-1295 Complex is offered as a standardized lyophilized dry solid in a 2R glass vial. Researchers evaluating somatotrope receptor cross-talk, secondary messenger synergy, and downstream endocrine kinetics study this matrix alongside complementary reference standards available on the site, such as Sermorelin, GHRP-2, GHRP-6, and MK-677.
The chemical and molecular parameters for each individual component in this dual-peptide matrix are detailed in the independent specification tables below:
| Compound Name | Hexarelin (Examorelin) |
|---|---|
| Biological Target | Pituitary GHSR-1a & Myocardial CD36 Scavenger Receptors |
| Chemical Classification | Synthetic Hexapeptide GH Secretagogue (GHRP Analogue) |
| Peptide Sequence | His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| CAS Number | 140703-51-1 |
| Chemical Formula | C47H58N12O6 |
| Molecular Weight | 887.05 g/mol |
| Primary Signal Transduction | Gq/11 → PLC → IP3 / DAG → Intracellular Ca2+ Efflux |
| Physical Appearance | White Lyophilized Solid Cake (Co-Lyophilized with CJC-1295) |
| Compound Name | CJC-1295 No DAC (Modified GRF 1-29) |
|---|---|
| Biological Target | Pituitary Somatotrope GHRH Receptors (GHRH-R) |
| Chemical Classification | Tetrasubstituted GHRH Analogue (29 Amino Acids) |
| Peptide Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| CAS Number | 863288-34-0 |
| Chemical Formula | C152H252N44O42 |
| Molecular Weight | 3367.97 g/mol |
| Primary Signal Transduction | Gαs → Adenylate Cyclase → cAMP → PKA Activation → CREB Phosphorylation |
| Structural Modifications | D-Ala2, Gln8, Ala15, Leu27 (Protease-Stabilized Tetrasubstitution) |
The convergent biochemical pathways and somatotropic targets of the Hexarelin / CJC-1295 matrix in laboratory research include:
When evaluating published scientific literature and neuroendocrine monographs for Hexarelin and CJC-1295:
In neuroendocrine and somatotropic axis research, secretagogues differ based on receptor selectivity, intracellular second-messenger pathways, and biological half-life:
| Compound / Reference | Chemical Structure & Class | Primary Receptor Targets | Primary Research Profile |
|---|---|---|---|
| Hexarelin / CJC-1295 | Dual Peptide: Hexapeptide + 29-AA Mod GRF | GHRH-R (cAMP/PKA) & GHSR-1a (IP3/Ca2+) + CD36 | Dual-pathway somatotrope co-stimulation; supra-additive secretory kinetics and CD36 metabolic signaling |
| Sermorelin | Native 29-Amino-Acid GHRH Fragment | Pituitary Somatotrope GHRH-R | Baseline GHRH receptor kinetics; physiological GHRH-R activation subject to standard DPP-4 cleavage |
| GHRP-2 | Synthetic Hexapeptide (6 Amino Acids) | Pituitary & Hypothalamic GHSR-1a | Selective ghrelin receptor stimulation; models baseline pulsatile growth hormone secretion with intermediate potency |
| GHRP-6 | Synthetic Hexapeptide (6 Amino Acids) | Pituitary GHSR-1a & Hypothalamic Ghrelin Targets | Pulsatile GH secretion paired with central orexigenic receptor activation |
| MK-677 (Ibutamoren) | Non-Peptide Spiroindoline Small Molecule | Pituitary & Hypothalamic GHSR-1a | Continuous, non-pulsatile ghrelin receptor occupancy; long-term somatotropic axis stimulation modeling |
Yes, Modern Aminos is a highly trusted vendor for high-purity research chemicals and reference peptides. Every batch of the Hexarelin / CJC-1295 (7.5mg / 5mg) Complex undergoes strict third-party analytical testing (including HPLC and Mass Spectrometry) to verify minimum 98%+ chemical purity for both peptides, exact sequence stoichiometry, verified molecular masses (887.05 g/mol and 3367.97 g/mol), and complete absence of heavy metals or synthesis impurities.
The 7.5mg Hexarelin to 5mg CJC-1295 ratio provides a calibrated balance between GHRH-R gene transcription and GHSR-1a exocytosis. Because CJC-1295 acts upstream on adenylate cyclase, a 5mg concentration provides sufficient signal transduction, while 7.5mg of Hexarelin accounts for its molecular weight (887.05 g/mol vs 3367.97 g/mol) to optimize stoichiometric molar coverage across both receptor populations.
CJC-1295 elevates cAMP and PKA to transcribe growth hormone mRNA and synthesize new hormone pools. Simultaneously, Hexarelin stimulates PLC, producing IP3 to release stored intracellular calcium (Ca2+) and drive immediate vesicle fusion. This convergence provides both the secretory trigger and the replenishment mechanism, resulting in supra-additive release without depleting cellular hormone reserves.
Unlike standard secretagogues that bind exclusively to GHSR-1a, Hexarelin functions as a selective ligand for the CD36 scavenger receptor present on myocardial and microvascular endothelial cells. In cellular models, CD36 ligation modulates cellular fatty acid flux, inhibits pro-apoptotic caspases, and preserves mitochondrial membrane potential during ischemic stress.
CJC-1295 No DAC (Modified GRF 1-29) incorporates four strategic amino acid substitutions into the native GHRH(1-29) sequence: D-Ala2, Gln8, Ala15, and Leu27. These modifications provide steric resistance against enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and oxidation, preserving receptor binding integrity during in vitro cellular incubation.
Hexarelin is prone to rapid GHSR-1a internalization and tachyphylaxis when administered alone. Co-incubating with CJC-1295 maintains active somatotrope transcription via the GHRH-R pathway, allowing researchers to study somatotrope output and evaluate secretagogue downregulatory dynamics across prolonged testing windows.
Modern Aminos uses gradient High-Performance Liquid Chromatography (HPLC) to achieve baseline chromatographic separation between Hexarelin and CJC-1295, verifying >98% chemical purity for both peaks. Mass Spectrometry (MS) then independently confirms the molecular mass of Hexarelin (887.05 g/mol) and CJC-1295 (3367.97 g/mol) to verify stoichiometric fill accuracy.
Lyophilized Hexarelin / CJC-1295 2R glass vials should be stored tightly sealed in a cool, dry environment (15°C to 25°C) or refrigerated (2°C to 8°C) for long-term preservation. Protect from direct sunlight, thermal extremes, and atmospheric moisture to maintain solid-state peptide stability.
Disclaimer: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.
By purchasing this product, you confirm that:
Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.
